Rallybio Looks To Deals To Grow ‘Transformative’ Rare Disease Pipeline

Emerging Company Profile: Armed with the insight of its ex-Alexion leaders, Rallybio is eyeing a spate of deals to develop and commercialize transformative drugs for rare diseases.